Table 2.
Newly proposed AMR genes
| Gene | Drug | Dominant allele | Mutation | Structural domain feature |
|---|---|---|---|---|
| Rv3848 | EMB, XDR | R: (25/26) | SNP | Outside transmembrane helical domain |
| embR | EMB | S: (2/37, 9/129) | SNP | Proximal to DNA-binding domain |
| Rv3129 | EMB | R: (8/11) | SNP | – |
| proC | EMB | S: (1/27, 11/127) | SNP | – |
| kdpC | EMB | R: (80/91) | SNP 11 | Inside transmembrane helical domain |
| oxcA | INH | R: (66/66, 26/26) | SNP 253 | TPP enzyme M-terminal domain |
| chp2 | ETA | R: (29/37, 34/60) | SNP 296 | DELs in mutagen and helical domain |
| lipD | ETA | R: (48/58, 8/12) | SNP 105 | Inside beta-lactamase domain |
| Rv3471c | ETA, XDR, SM | R: (48/50) | SNP 64 | Inside Cupin 1 domain |
| mmpL11 | PAS | R: (35/48) | SNP 520 | – |
| Rv0044c | PAS | R: (13/13) | DEL 137–264 | BAC Luciferase |
| Rv0954 | PAS | R: (34/46, 4/6) | SNP 223 | Different mutational backgrounds |
| Rv2560 | PZA | S: (6/41) | DEL 1–80 | Compositional bias Proline-rich domain |
| Rv2090 | RIF, INH | S: (9/67, 6/46, 5/51) | SNP 295 | – |
| lpqZ | RIF | S: (10/91, 12/79) | SNP 119 | Within opuAC signaling domain |
| Rv1597 | RIF, MDR, INH | R: (18/19) | SNP 196 | No mutation in methyltransferase domain |
| Rv1543 | RIF, MDR | S: (10/84, 12/80) | SNP 128 | Proximal to binding domain |
| nuoL | MDR, PAS | R: (17/17) | SNP 503 | Outside transmembrane helical domain |
| dnaA | SM | R: (22/22) | SNP 233 | Proximal to nucleotide binding domain 213 |
| yajC | SM | R: (30/30) | SNP 87 | Within transmembrane helical domain |
| accD5 | OFX, MDR | R: (16/16) | SNP 127 | Within CoA carboxyltransferase domain |
| Rv3041c | RIF, OFX, SM, MDR | R: (20/28, 25/44) | SNP 140 | SNP in ATP binding domain |
| VapC21 | XDR | R: (14/23, 14/20) | DEL 88–138 | Within second magnesium binding domain |
The mutation column represents the distinguishing mutation for the resistant or susceptible-dominant allele(s). Abbreviations: R, resistant; S, susceptible; EMB, ethambutol; PAS, para-aminosalicylic acid; INH, isoniazid; PZA, pyrazinamide; RMP, rifampicin; SM, streptomycin; OFX, ofloxacin; ETA, ethionamide; MDR, multidrug resistant; XDR, extensively-drug resistant